+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Coronary Syndrome: Global Strategic Business Report

  • PDF Icon

    Report

  • 182 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227823

Quick Summary:

In an increasingly dynamic healthcare environment, the Global Acute Coronary Syndrome Market is projected to expand dramatically, with a revised forecast predicting the industry to reach $17.6 Billion by 2030. This impressive growth trajectory, from an estimated valuation of $7.9 Billion in 2022, underscores the critical potential of investment opportunities within this economically significant market.

For senior executives seeking to stay abreast of evolving trends, this comprehensive report offers an invaluable roadmap of the Acute Coronary Syndrome market. Notably, it shows the U.S. market is valued at $2.1 billion, while China's fateful expansion is expected to surge at a 16.6% CAGR, reaching $4.5 billion by 2030. Including critical insights into growing geographical markets, such as Japan and Canada, and solid performers like Germany, the report equips visionaries with the intelligence needed to navigate the future of the healthcare landscape.

Global Acute Coronary Syndrome Market to Reach $17.6 Billion by 2030

The global market for Acute Coronary Syndrome estimated at US$7.9 Billion in the year 2022, is projected to reach a revised size of US$17.6 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2022-2030.

The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 16.6% CAGR

The Acute Coronary Syndrome market in the U.S. is estimated at US$2.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 10.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.

Select Competitors (Total 62 Featured) -

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Acute Coronary Syndrome

What is the estimated value of the Global Market for Acute Coronary Syndrome?

The Global Market for Acute Coronary Syndrome was estimated to be valued at $7.9 Billion in 2022.

What is the growth rate of the Global Market for Acute Coronary Syndrome?

The growth rate of the Global Market for Acute Coronary Syndrome is 10.5%, with an estimated value of $17.6 Billion by 2030.

What is the forecasted size of the Global Market for Acute Coronary Syndrome?

The Global Market for Acute Coronary Syndrome is estimated to be worth $17.6 Billion by 2030.

Who are the key companies in the Global Market for Acute Coronary Syndrome?

Key companies in the Global Market for Acute Coronary Syndrome include Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Biological E. Ltd., Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann and La Roche AG.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Acute Coronary Syndrome - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Acute Coronary Syndrome Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 5: USA Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 6: USA Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
CANADA
  • Table 7: Canada Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 8: Canada Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
JAPAN
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 9: Japan Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 10: Japan Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
CHINA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 11: China Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 12: China Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
EUROPE
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 13: Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: Europe Historic Review for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: Europe 18-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
FRANCE
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 16: France Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 17: France Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
GERMANY
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 18: Germany Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 19: Germany Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
ITALY
  • Table 20: Italy Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: Italy Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
UNITED KINGDOM
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 22: UK Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 23: UK Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
SPAIN
  • Table 24: Spain Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 25: Spain Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
RUSSIA
  • Table 26: Russia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Russia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
REST OF EUROPE
  • Table 28: Rest of Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 29: Rest of Europe Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
ASIA-PACIFIC
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 31: Asia-Pacific Historic Review for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 32: Asia-Pacific 18-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
AUSTRALIA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • Table 33: Australia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 34: Australia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
INDIA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • Table 35: India Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: India Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
SOUTH KOREA
  • Table 37: South Korea Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 38: South Korea Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
REST OF ASIA-PACIFIC
  • Table 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 40: Rest of Asia-Pacific Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
LATIN AMERICA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • Table 41: Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 42: Latin America Historic Review for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 43: Latin America 18-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
ARGENTINA
  • Table 44: Argentina Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Argentina Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
BRAZIL
  • Table 46: Brazil Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 47: Brazil Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
MEXICO
  • Table 48: Mexico Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 49: Mexico Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
REST OF LATIN AMERICA
  • Table 50: Rest of Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Rest of Latin America Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
MIDDLE EAST
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • Table 52: Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 53: Middle East Historic Review for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 54: Middle East 18-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
IRAN
  • Table 55: Iran Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 56: Iran Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
ISRAEL
  • Table 57: Israel Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 58: Israel Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
SAUDI ARABIA
  • Table 59: Saudi Arabia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Saudi Arabia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
UNITED ARAB EMIRATES
  • Table 61: UAE Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 62: UAE Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
REST OF MIDDLE EAST
  • Table 63: Rest of Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 64: Rest of Middle East Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
AFRICA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
  • Table 65: Africa Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Africa Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company